Resiniferatoxin in the treatment of street ketamine associated lower urinary tract symptoms
-
摘要: 目的：探讨RTX膀胱灌注治疗氯胺酮相关性下尿路症状的有效性和安全性。方法：收治滥用氯胺酮1.5~6年患者16例，均因严重下尿路症状就诊，所有患者均行RTX 1次性膀胱灌注，观察用药前及用药后1周、1个月、3个月时患者的临床症状情况（每日排尿次数、排尿量、尿疼痛程度评分）和生活质量评分（QOL）情况。结果：患者用药前及用药后1周、1个月和3个月时每日排尿次数分别为（48.41±10.77）、（14.30±4.77）、（14.63±3.70）和（15.19±4.06）次，用药后排尿次数明显减少；最大排尿量分别为（104.26±79.31）、（167.41±67.46）、（188.89±62.35）和（171.85±65.11）ml，用药后排尿量增加；疼痛程度评分分别为（6.74±1.38）、（3.89±1.15）、（4.63±1.31）和（4.85±1.67）分，较用药前明显下降，上述指标与用药前相比差异有统计学意义。患者用药前后生活质量评分分别为（5.92±0.51）、（5.20±0.47）、（5.33±0.46）、（5.34±0.51）分，差异无统计学意义。所有患者均坚持完成试验，使用RTX后患者生命体征均平稳，无全身不良反应。结论：用RTX膀胱灌注治疗能有效缓解氯胺酮相关性下尿路症状患者的临床症状和改善其生活质量，且耐受性及安全性好。Abstract: Objective: To investigate the safety and efficacy of intravesical resiniferatoxin (RTX) therapy for the patients with street ketamine associated lower urinary tract symptoms(LUTs).Method: A total of 16 ketamine abusers, presented with severe lower urinary tract symptoms were collected.All of them received once intravesical RTX therapy. Clinical symptoms (micturition frequency per day, maximal micturition volume and odynuria degree score), and quality of life score were assessed at baseline and then again after 1 week, 1 month and 3 months of treatment. Side effects was recorded. Result: After 1 week, 1 month and 3 months of treatment, micturition frequency per day(the baseline vs 1 week, 1 month and 3 months after treatment:(48.41±10.77), (14.30±4.77), (14.63±3.70) and (15.19±4.06) and odynuria degree score (the baseline vs 1 W, 1 M and 3 M after treatment:(6.74±1.38), (3.89±1.15), (4.63±1.31) and (4.85±1.67) were significantly decreased, and maximal micturition volume, the baseline vs 1 week, 1 month and 3 months after treatment:(104.26±79.31), (167.41±67.46), (188.89±62.35) and (171.85±65.11) ml was significantly increased. There were significantly differences between the baseline and after the treatment. After 1 week, 1 month and 3 months of treatment, quality of life score:the baseline vs 1 week, 1 month and 3 months after treatment:(5.92±0.51), (5.20±0.47), (5.33±0.46), (5.34±0.51), there were no significantly difference compared with the baseline. There were no serious adverse events after intravesical RTX therapy. No patients withdrawled. Conclusion: Intravesical RTX therapy can effectively relieve clinical symptom of street ketamine associated LUTs and improve their quality of life and is well tolerated.
-
Key words:
- ketamine /
- resiniferatoxin /
- bladder /
- lower urinary tract symptoms
-
-
[1] Cruz F, Dinis P. Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms[J]. Neurourol Urodyn, 2007, 26:920-927.
[2] 杜鹏, 朱绪辉, 陈松, 等. 膀胱灌注RTX治疗间质性膀胱炎的临床研究[J]. 临床泌尿外科杂志, 2008, 23(10):755-757.
[3] Shahani R, Streutker C, Dickson B, et al. Ketamine-associated ulcerative cystitis:a new clincal entity[J]. Urology, 2007, 69:810-812.
[4] Chu P S, Kwok S C, Lam K M, et al. ‘Street ketamine’-associated bladder dysfunction:a report of ten cases[J]. Hong Kong Med J, 2007, 13:311-313.
[5] Chu P S, Ma W K, Wong S C, et al. The destruction of the lower urinary tract by ketamine abuse:a new syndrome[J]. BJU Int, 2008, 102:1616-1622.
[6] Chen C H, Lee M H, Chen Y C, et al. Ketamine-snorting associated cystitis[J]. J Formos Med Assoc, 2011, 110:787-791.
[7] Meng E, Chang H Y, Chang S Y, et al. Involvement of purinergic neurotransmission in ketamine induced bladder dysfunction[J]. J Urol, 2011, 186:1134-1141.
[8] Yoshimura N, Erdman S L, Snider M W, et al. Effects of spinal cord injury on neurofilament immunoreactivity and capsaicin sensitivity in rat dorsal root ganglion neurons innervating the urinary bladder[J]. Neuroscience, 1998, 83:633-643.
[9] Szallasi A, Blumberg P M. Vanilloid (Capsaicin) receptors and mechanisms[J]. Pharmacol Rev, 1999, 51:159-212.
[10] Nolano M, Simone D A, Wendelschafer-Crabb G, et al. Topical capsaicin in humans:parallel loss of epidermal nerve fibers and pain sensation[J]. Pain, 1999, 81:135-145.
-
计量
- 文章访问数: 66
- PDF下载数: 62
- 施引文献: 0
下载: